KNOWING WHICH DRUGS TO TEST FOR EACH PATIENT
The number of drugs we are able to test is dependent upon the size and condition of the biopsy specimen we receive. It is why we communicate with the surgeon or other physician who will be performing the biopsy procedure and also with the pathologist, if one will be involved.
Drug test panels are individually designated for specifically each patient by Dr. Weisenthal. Dr. Weisenthal takes into account the patient’s diagnosis, previous treatment history, and other clinical factors.
Dr. Weisenthal includes within his drug selections the broadest possible range of drugs that are appropriate for each patient. This begins by designating all drugs known to have activity in a certain cancer type. Dr. Weisenthal then uses his skills as an oncologist, his expertise as inventor of the tests and experienced gained from having performed testing for thousands of cancer patents, his pharmacology insight, and his knowledge of the medical literature to expand the test panel to include drugs or drug combinations for which there is rational support for potential patient benefit. The goal is to afford to each patient the greatest opportunity for benefit.
In addtion, specific drug requests by the treating physician are given priority. Clinicians are always invited to discuss drug choices with Dr. Weisenthal in advance of testing.
If high anti-tumor activity is observed in a lesser-known drug or drug combination, Dr. Weisenthal explores underlying reasons for the activity, both cognitively and through searches of the world’s medical literature. When appropriate, Dr. Weisenthal provides journal articles from peer-reviewed clinical studies in which activity for his recommended therapy was observed. He also provides information relating to dosing and administration schedules as well as reported drug side-effects.